IN THE NEWS
September 23, 2016:
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference
September 12, 2016:
Fortress Biotech Completes Tender Offer for Shares of National Holdings Corporation
August 11, 2016:
Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 - A Novel Third Generation EGFR Inhibitor
August 9, 2016:
Fortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
QUICK LINKS
PIPELINE
| Preclinical | Phase I | Phase II | Phase III | Commercialization | ||||
| Journey Medical Corporation | ||||||||
| Luxamend Wound Cream | ||||||||
| Ceracade | ||||||||
| Dermasorb HC (Co-Promote) | ||||||||
| Avenue Therapeutics | ||||||||
| IV Tramadol | (start pending) | |||||||
| Helocyte, Inc. | ||||||||
| Triplex (CMV Vaccine) | ||||||||
| PepVax (CMV Vaccine) | ||||||||
| Pentamer (CMV Vaccine) | ||||||||
| Escala Therapeutics | ||||||||
| ManNAc (GNE Myopathy) | ||||||||
| ManNAc (Nephropathies) | ||||||||
| Mustang Bio | ||||||||
| CD123 CAR (AML) | ||||||||
| IL13Ra2-specific CAR (Malignant Glioma) | ||||||||
| Checkpoint Therapeutics | ||||||||
| CK-102 PARP | ||||||||
| Anti-PD-L1 | ||||||||
| Anti-GITR | ||||||||
| Anti-CAIX | ||||||||
| CK-101 EGFR | ||||||||
| CK-103 BET | ||||||||
| Fortress Biotech | ||||||||
| CNDO-109 | ||||||||
